[Long-term therapy in childhood epilepsy].
Recommendations for treatment of pediatric epileptic patients issued by three different sources are analyzed. 1) The review on treatment-resistant epilepsy published in 2003 by the Agency for Healthcare Research and Quality. 2) Articles written by the Cochrane Epilepsy Group available in January 2004. 3) A personal review of papers presenting a pediatric interest published between 1998 and 2003. Most of the data are related to the use of new anti-epileptic drugs. The therapeutic effect can be evaluated only when considering the etiology or the epileptic syndrome. Few studies have been devoted to the therapeutic benefit in terms of the child's quality-of-life.
Raffo
E
E
Service de Médecine Infantile 1, Hôpital d'Enfants, CHU de Nancy, 1 rue du Morvan, 54500 Vandoeuvre-lès-Nancy, France. e.raffo@chu-nancy.fr
D000293:Adolescent; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004041:Dietary Fats / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000178:diet therapy / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007659:Ketones / Q000378:metabolism; D012196:Review Literature as Topic; D013997:Time Factors; D016896:Treatment Outcome
D000927:Anticonvulsants; D004041:Dietary Fats; D007659:Ketones